{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T17:45:56Z","timestamp":1775065556148,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:00:00Z","timestamp":1715817600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:00:00Z","timestamp":1715817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiol Ther"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s40119-024-00371-8","type":"journal-article","created":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T12:01:27Z","timestamp":1715860887000},"page":"453-463","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Is There an Alternative Oral Anticoagulation to Vitamin-K-Antagonists for Patients with Mechanical Aortic Valve Replacement? \u2013 A Literature Review"],"prefix":"10.1007","volume":"13","author":[{"given":"Stephen","family":"Gerfer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thorsten","family":"Wahlers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elmar","family":"Kuhn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,16]]},"reference":[{"issue":"24","key":"371_CR1","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1016\/j.jacc.2016.09.958","volume":"68","author":"GD Dangas","year":"2016","unstructured":"Dangas GD, Weitz JI, Giustino G, Makkar R, Mehran R. Prosthetic heart valve thrombosis. J Am Coll Cardiol. 2016;68(24):2670\u201389.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"371_CR2","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.imbio.2016.06.005","volume":"221","author":"R Wiegner","year":"2016","unstructured":"Wiegner R, Chakraborty S, Huber-Lang M. Complement-coagulation crosstalk on cellular and artificial surfaces. Immunobiology. 2016;221(10):1073\u20139.","journal-title":"Immunobiology"},{"issue":"8","key":"371_CR3","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.115.002322","volume":"4","author":"IH Jaffer","year":"2015","unstructured":"Jaffer IH, Stafford AR, Fredenburgh JC, Whitlock RP, Chan NC, Weitz JI. Dabigatran is less effective than warfarin at attenuating mechanical heart valve-induced thrombin generation. J Am Heart Assoc. 2015;4(8): e002322.","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"371_CR4","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.thromres.2009.11.028","volume":"125","author":"E Stavrou","year":"2010","unstructured":"Stavrou E, Schmaier AH. Factor XII: what does it contribute to our understanding of the physiology and pathophysiology of hemostasis & thrombosis. Thromb Res. 2010;125(3):210\u20135.","journal-title":"Thromb Res"},{"issue":"8","key":"371_CR5","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1161\/ATVBAHA.107.141911","volume":"27","author":"N Mackman","year":"2007","unstructured":"Mackman N, Tilley RE, Key NS. Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arterioscler Thromb Vasc Biol. 2007;27(8):1687\u201393.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"371_CR6","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1136\/hrt.2005.071183","volume":"93","author":"R Roudaut","year":"2007","unstructured":"Roudaut R, Serri K, Lafitte S. Thrombosis of prosthetic heart valves: diagnosis and therapeutic considerations. Heart. 2007;93(1):137\u201342.","journal-title":"Heart"},{"issue":"13","key":"371_CR7","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1161\/CIRCULATIONAHA.118.035612","volume":"138","author":"A Aimo","year":"2018","unstructured":"Aimo A, Giugliano RP, De Caterina R. Non-vitamin K antagonist oral anticoagulants for mechanical heart valves: is the door still open? Circulation. 2018;138(13):1356\u201365.","journal-title":"Circulation"},{"issue":"5","key":"371_CR8","first-page":"e35","volume":"143","author":"CM Otto","year":"2021","unstructured":"Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP 3rd, Gentile F, et al. 2020 ACC\/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American college of cardiology\/American heart association joint committee on clinical practice guidelines. Circulation. 2021;143(5):e35\u201371.","journal-title":"Circulation"},{"key":"371_CR9","doi-asserted-by":"publisher","DOI":"10.1093\/ejcts\/ezac209","author":"A Vahanian","year":"2021","unstructured":"Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, et al. ESC\/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2021. https:\/\/doi.org\/10.1093\/ejcts\/ezac209.","journal-title":"Eur Heart J"},{"issue":"2","key":"371_CR10","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1161\/01.CIR.89.2.635","volume":"89","author":"SC Cannegieter","year":"1994","unstructured":"Cannegieter SC, Rosendaal FR, Briet E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation. 1994;89(2):635\u201341.","journal-title":"Circulation"},{"issue":"7","key":"371_CR11","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1136\/hrt.2003.025049","volume":"90","author":"C Seiler","year":"2004","unstructured":"Seiler C. Management and follow up of prosthetic heart valves. Heart. 2004;90(7):818\u201324.","journal-title":"Heart"},{"issue":"12","key":"371_CR12","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1592\/phco.2005.25.12.1801","volume":"25","author":"IA Orensky","year":"2005","unstructured":"Orensky IA, Holdford DA. Predictors of noncompliance with warfarin therapy in an outpatient anticoagulation clinic. Pharmacotherapy. 2005;25(12):1801\u20138.","journal-title":"Pharmacotherapy"},{"issue":"3","key":"371_CR13","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1001\/archinte.167.3.229","volume":"167","author":"SE Kimmel","year":"2007","unstructured":"Kimmel SE, Chen Z, Price M, Parker CS, Metlay JP, Christie JD, et al. The influence of patient adherence on anticoagulation control with warfarin: results from the international normalized ratio adherence and genetics (IN-RANGE) study. Arch Intern Med. 2007;167(3):229\u201335.","journal-title":"Arch Intern Med"},{"issue":"4","key":"371_CR14","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1067\/mtc.2002.121162","volume":"123","author":"EG Butchart","year":"2002","unstructured":"Butchart EG, Payne N, Li HH, Buchan K, Mandana K, Grunkemeier GL. Better anticoagulation control improves survival after valve replacement. J Thorac Cardiovasc Surg. 2002;123(4):715\u201323.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"371_CR15","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/1477-7525-9-91","volume":"9","author":"Q Almeida Gde","year":"2011","unstructured":"Almeida Gde Q, Noblat Lde A, Passos LC, do Nascimento HF. Quality of life analysis of patients in chronic use of oral anticoagulant: an observational study. Health Qual Life Outcomes. 2011;9:91.","journal-title":"Health Qual Life Outcomes"},{"issue":"12","key":"371_CR16","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139\u201351.","journal-title":"N Engl J Med"},{"issue":"10","key":"371_CR17","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883\u201391.","journal-title":"N Engl J Med"},{"issue":"1","key":"371_CR18","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1161\/STROKEAHA.117.018395","volume":"49","author":"M Proietti","year":"2018","unstructured":"Proietti M, Romanazzi I, Romiti GF, Farcomeni A, Lip GYH. Real-world use of apixaban for stroke prevention in atrial fibrillation: a systematic review and meta-analysis. Stroke. 2018;49(1):98\u2013106.","journal-title":"Stroke"},{"issue":"1","key":"371_CR19","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1160\/TH08-10-0708","volume":"101","author":"JE Eikelboom","year":"2009","unstructured":"Eikelboom JE, Weitz JI. Dabigatran etexilate for prevention of venous thromboembolism. Thromb Haemost. 2009;101(1):2\u20134.","journal-title":"Thromb Haemost"},{"issue":"1","key":"371_CR20","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/j.1538-7836.2004.01100.x","volume":"3","author":"BI Eriksson","year":"2005","unstructured":"Eriksson BI, Dahl OE, Buller HR, Hettiarachchi R, Rosencher N, Bravo ML, et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost. 2005;3(1):103\u201311.","journal-title":"J Thromb Haemost"},{"issue":"6","key":"371_CR21","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1016\/j.jtcvs.2011.02.011","volume":"141","author":"SH McKellar","year":"2011","unstructured":"McKellar SH, Abel S, Camp CL, Suri RM, Ereth MH, Schaff HV. Effectiveness of dabigatran etexilate for thromboprophylaxis of mechanical heart valves. J Thorac Cardiovasc Surg. 2011;141(6):1410\u20136.","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"6","key":"371_CR22","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.ahj.2012.03.011","volume":"163","author":"F Van de Werf","year":"2012","unstructured":"Van de Werf F, Brueckmann M, Connolly SJ, Friedman J, Granger CB, Hartter S, et al. A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: THE Randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN). Am Heart J. 2012;163(6):931-7.e1.","journal-title":"Am Heart J"},{"issue":"13","key":"371_CR23","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","volume":"369","author":"JW Eikelboom","year":"2013","unstructured":"Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013;369(13):1206\u201314.","journal-title":"N Engl J Med"},{"issue":"4","key":"371_CR24","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1056\/NEJMc1315004","volume":"370","author":"S Sharma","year":"2014","unstructured":"Sharma S, Singh S. Dabigatran in patients with mechanical heart valves. N Engl J Med. 2014;370(4):381\u20132.","journal-title":"N Engl J Med"},{"issue":"13","key":"371_CR25","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1056\/NEJMe1310399","volume":"369","author":"EM Hylek","year":"2013","unstructured":"Hylek EM. Dabigatran and mechanical heart valves\u2013not as easy as we hoped. N Engl J Med. 2013;369(13):1264\u20136.","journal-title":"N Engl J Med"},{"issue":"3","key":"371_CR26","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1111\/jth.12500","volume":"12","author":"JW Eikelboom","year":"2014","unstructured":"Eikelboom JW, Brueckmann M, van de Werf F. Dabigatran versus warfarin in patients with mechanical heart valves: reply. J Thromb Haemost. 2014;12(3):426.","journal-title":"J Thromb Haemost"},{"issue":"1","key":"371_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40262-013-0100-7","volume":"53","author":"W Mueck","year":"2014","unstructured":"Mueck W, Stampfuss J, Kubitza D, Becka M. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet. 2014;53(1):1\u201316.","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"371_CR28","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1007\/s40262-019-00775-z","volume":"58","author":"W Byon","year":"2019","unstructured":"Byon W, Garonzik S, Boyd RA, Frost CE. Apixaban: a clinical pharmacokinetic and pharmacodynamic review. Clin Pharmacokinet. 2019;58(10):1265\u201379.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"371_CR29","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s11239-011-0621-6","volume":"32","author":"A Kaeberich","year":"2011","unstructured":"Kaeberich A, Reindl I, Raaz U, Maegdefessel L, Vogt A, Linde T, et al. Comparison of unfractionated heparin, low-molecular-weight heparin, low-dose and high-dose rivaroxaban in preventing thrombus formation on mechanical heart valves: results of an in vitro study. J Thromb Thrombolysis. 2011;32(4):417\u201325.","journal-title":"J Thromb Thrombolysis"},{"issue":"5","key":"371_CR30","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1093\/ejcts\/ezt545","volume":"45","author":"LE Greiten","year":"2014","unstructured":"Greiten LE, McKellar SH, Rysavy J, Schaff HV. Effectiveness of rivaroxaban for thromboprophylaxis of prosthetic heart valves in a porcine heterotopic valve model. Eur J Cardiothorac Surg. 2014;45(5):914\u20139.","journal-title":"Eur J Cardiothorac Surg"},{"issue":"6","key":"371_CR31","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.amjcard.2018.06.015","volume":"122","author":"AR Duraes","year":"2018","unstructured":"Duraes AR, Bitar YSL, Lima MLG, Santos CC, Schonhofen IS, Filho JAL, et al. Usefulness and safety of rivaroxaban in patients following isolated mitral valve replacement with a mechanical prosthesis. Am J Cardiol. 2018;122(6):1047\u201350.","journal-title":"Am J Cardiol"},{"issue":"4","key":"371_CR32","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s40268-018-0249-5","volume":"18","author":"AR Duraes","year":"2018","unstructured":"Duraes AR, de Souza Lima Bitar Y, Filho JAL, Schonhofen IS, Camara EJN, Roever L, et al. Rivaroxaban versus warfarin in patients with mechanical heart valve: rationale and design of the RIWA study. Drugs RD. 2018;18(4):303\u20138.","journal-title":"Drugs RD."},{"key":"371_CR33","doi-asserted-by":"publisher","DOI":"10.1007\/s40256-020-00449-3","author":"AR Duraes","year":"2020","unstructured":"Duraes AR, de Souza Lima Bitar Y, Schonhofen IS, Travassos KSO, Pereira LV, Filho JAL, et al. Rivaroxaban versus warfarin in patients with mechanical heart valves open-label proof-of-concept trial-the RIWA study. Am J Cardiovasc Drugs. 2020. https:\/\/doi.org\/10.1007\/s40256-020-00449-3.","journal-title":"Am J Cardiovasc Drugs"},{"key":"371_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.thromres.2019.12.005","volume":"186","author":"E Roost","year":"2020","unstructured":"Roost E, Weber A, Alberio L, Englberger L, Reineke D, Keller D, et al. Rivaroxaban in patients with mechanical heart valves: a pilot study. Thromb Res. 2020;186:1\u20136.","journal-title":"Thromb Res"},{"issue":"5","key":"371_CR35","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1161\/ATVBAHA.116.308649","volume":"37","author":"PA Lester","year":"2017","unstructured":"Lester PA, Coleman DM, Diaz JA, Jackson TO, Hawley AE, Mathues AR, et al. Apixaban versus warfarin for mechanical heart valve thromboprophylaxis in a swine aortic heterotopic valve model. Arterioscler Thromb Vasc Biol. 2017;37(5):942\u20138.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"371_CR36","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ahj.2020.06.014","volume":"227","author":"OK Jawitz","year":"2020","unstructured":"Jawitz OK, Wang TY, Lopes RD, Chavez A, Boyer B, Kim H, et al. Rationale and design of PROACT Xa: a randomized, multicenter, open-label, clinical trial to evaluate the efficacy and safety of apixaban versus warfarin in patients with a mechanical On-X aortic heart valve. Am Heart J. 2020;227:91\u20139.","journal-title":"Am Heart J"},{"issue":"7","key":"371_CR37","doi-asserted-by":"publisher","first-page":"2300067","DOI":"10.1056\/EVIDoa2300067","volume":"2","author":"T Wang","year":"2023","unstructured":"Wang T, Svensson L, Wen J, Vekstein A, Gerdisch M, Rao V, et al. Apixaban or warfarin in patients with an On-X mechanical aortic valve. NEJM Evid. 2023;2(7):2300067.","journal-title":"NEJM Evid"},{"issue":"5","key":"371_CR38","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1161\/01.CIR.72.5.1059","volume":"72","author":"CK Mok","year":"1985","unstructured":"Mok CK, Boey J, Wang R, Chan TK, Cheung KL, Lee PK, et al. Warfarin versus dipyridamole-aspirin and pentoxifylline-aspirin for the prevention of prosthetic heart valve thromboembolism: a prospective randomized clinical trial. Circulation. 1985;72(5):1059\u201363.","journal-title":"Circulation"},{"key":"371_CR39","doi-asserted-by":"publisher","DOI":"10.1055\/s-0041-1736242","author":"S Gerfer","year":"2023","unstructured":"Gerfer S, Grandoch M, Wahlers T, Kuhn E. Factor Xa Inhibitors for patients after mechanical heart valve replacement? Thorac Cardiovasc Surg. 2023. https:\/\/doi.org\/10.1055\/s-0041-1736242.","journal-title":"Thorac Cardiovasc Surg"},{"issue":"7","key":"371_CR40","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1046\/j.1538-7836.2003.00298.x","volume":"1","author":"KG Mann","year":"2003","unstructured":"Mann KG, Brummel K, Butenas S. What is all that thrombin for? J Thromb Haemost. 2003;1(7):1504\u201314.","journal-title":"J Thromb Haemost"},{"issue":"5","key":"371_CR41","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1161\/ATVBAHA.117.309223","volume":"37","author":"NC Chan","year":"2017","unstructured":"Chan NC, Weitz JI, Eikelboom JW. Anticoagulation for mechanical heart valves: will oral factor Xa inhibitors be effective? Arterioscler Thromb Vasc Biol. 2017;37(5):743\u20135.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"371_CR42","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ahj.2010.05.005","volume":"160","author":"M Torella","year":"2010","unstructured":"Torella M, Torella D, Chiodini P, Franciulli M, Romano G, De Santo L, et al. LOWERing the INtensity of oral anticoaGulant Therapy in patients with bileaflet mechanical aortic valve replacement: results from the \u201cLOWERING-IT\u201d Trial. Am Heart J. 2010;160(1):171\u20138.","journal-title":"Am Heart J"}],"container-title":["Cardiology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-024-00371-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40119-024-00371-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-024-00371-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T15:27:08Z","timestamp":1724081228000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40119-024-00371-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,16]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["371"],"URL":"https:\/\/doi.org\/10.1007\/s40119-024-00371-8","relation":{},"ISSN":["2193-8261","2193-6544"],"issn-type":[{"value":"2193-8261","type":"print"},{"value":"2193-6544","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,16]]},"assertion":[{"value":"8 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We hereby certify that there is no conflict of interest for Stephen Gerfer, Thorsten Wahlers, and Elmar Kuhn.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}